NASDAQ · ADPT
Healthcare · Biotechnology
$28.17
Down-$1.53 (-5.43%)
Updated Oct 31, 2026, 1:25 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ADPT
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 29, 2026
ADPT closed at $28.17 after 20 trading sessions, down 0.63% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 29, 2026 | $28.00 | $28.805 | $27.91 | $28.17 | 2.59M |
| Oct 28, 2026 | $27.275 | $29.05 | $27.275 | $28.37 | 2.32M |
| Oct 27, 2026 | $26.36 | $28.00 | $26.05 | $27.66 | 1.54M |
| Oct 26, 2026 | $25.66 | $26.45 | $25.24 | $26.27 | 1.16M |
| Oct 23, 2026 | $24.23 | $25.62 | $23.82 | $25.51 | 1.92M |
| Oct 22, 2026 | $25.39 | $25.68 | $23.91 | $24.41 | 1.26M |
| Oct 21, 2026 | $24.36 | $25.74 | $24.25 | $25.33 | 1.72M |
| Oct 20, 2026 | $24.07 | $24.89 | $23.85 | $24.42 | 1.25M |
| Oct 19, 2026 | $24.30 | $24.88 | $23.855 | $23.95 | 1.19M |
| Oct 16, 2026 | $25.41 | $25.65 | $23.95 | $24.02 | 1.95M |
| Oct 15, 2026 | $25.47 | $25.91 | $24.88 | $25.58 | 1.73M |
| Oct 14, 2026 | $24.59 | $26.33 | $24.33 | $25.62 | 1.88M |
| Oct 13, 2026 | $25.38 | $25.86 | $24.66 | $25.28 | 1.95M |
| Oct 12, 2026 | $26.31 | $26.492 | $24.76 | $25.57 | 3.12M |
| Oct 9, 2026 | $26.11 | $26.85 | $25.969 | $26.49 | 1.53M |
| Oct 8, 2026 | $26.00 | $26.14 | $25.12 | $26.09 | 2.65M |
| Oct 7, 2026 | $26.39 | $26.93 | $25.865 | $26.28 | 2.12M |
| Oct 6, 2026 | $30.221 | $30.74 | $26.85 | $26.90 | 2.53M |
| Oct 5, 2026 | $28.57 | $29.86 | $28.16 | $29.84 | 1.43M |
| Oct 2, 2026 | $27.59 | $28.41 | $27.31 | $28.35 | 1.58M |
The latest Smart Investors Daily articles mentioning ADPT.
Company
Market Activity
Research & News
ADPT research
Company profile and research snapshot.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | Morgan Stanley | Equal-Weight | — |
| Oct 13, 2026 | TD Cowen | Buy | — |
| Oct 1, 2026 | Guggenheim | Buy | — |
| Sep 29, 2026 | Goldman Sachs | Buy | — |
| Sep 22, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
SeekingAlpha · Oct 27, 2026
Adaptive Biotechnologies gains from new myeloma MRD guidelines, strong clonoSEQ growth, and refinancing tailwinds. Read why ADPT stock is a buy.
Yahoo · Oct 20, 2026
Tempus AI (TEM) stock has lost 17.3% over the past month, while the S&P 500 gained 0.6%. The company still grew sales 22% in its latest quarter, but the risk worth your attention lies with the few drugmakers that license its data. One of them is a very large client. Which drugmaker is it, and how long does its deal with Tempus AI run.
Yahoo · Oct 14, 2026
SEATTLE, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the third quarter 2026 after market close on Wednesday, November 4, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. East
Benzinga · Oct 13, 2026
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $28 to $32.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ADPT.
